The President of Private Healthcare Australia, Rob Bransby, has announced the appointment of Dr Rachel David to the position of Chief Executive Officer.
“Following an extensive search the private health insurance industry is extremely fortunate to have recruited someone of Dr David’s calibre and experience. This is an important period for the PHI Industry and Dr David’s extensive career in healthcare policy, in both Government and the private sector ensures she is vastly qualified for this challenging and rewarding role.
“The PHI Industry is looking forward to working with Dr David who is exceptionally qualified to bring about positive change for health consumers and to increase the value of PHI to more than 13 million privately insured Australians,” he said.
A former medical practitioner, Dr David is an expert on healthcare policy and financing, with a special interest in evidence-based healthcare and use of data to drive best practice. She is passionate about the role of consumer choice in healthcare decision-making.
She has worked at the highest levels of Government as senior adviser to a former Federal Health Minister, and in business as the founding practice manager of the healthcare and Australian government sector practice at McKinsey & Company.
As part of the senior management team of CSL Ltd, Australia’s leading biotechnology company, Dr David played a pivotal role in making the cervical cancer vaccine Gardasil available to Australian women.
Currently the Director of Government Affairs and Policy for the Johnson & Johnson Family of Companies in Australia and New Zealand, Dr David has worked with the international pharmaceutical biotechnology and medical devices industries for more than a decade.
Dr David is expected to take up the position in late January 2016.
Media contact: Steve Fanner 02 62021000